Relative Bioavailability Study of a Fixed-dose Combination Dolutegravir/Abacavir/Lamivudine Dispersible Tablet

Inclusion Criteria

- Male or female aged between 18 and 65 years of age inclusive, at the time of signing
the informed consent.

- Healthy as determined by the investigator or medically qualified designee based on a
medical evaluation including medical history, physical examination, laboratory tests
and cardiac evaluation (history and ECG). A subject with a clinical abnormality or
laboratory parameter(s) which is/are not specifically listed in the inclusion or
exclusion criteria, outside the reference range for the population being studied may
be included only if the investigator agree and document that the finding is unlikely
to introduce additional risk factors and will not interfere with the study procedures.

- Body weight >=50 kilogram (kg) for males and >=45 kg for females and body mass index
(BMI) within the range 18.5-31.0 kg/m^2 (inclusive).

- Male or female

- Females of non-reproductive potential defined as pre-menopausal females with
documented tubal ligation, documented hysteroscopic tubal occlusion procedure with
follow-up confirmation of bilateral tubal occlusion, hysterectomy, documented
bilateral oophorectomy, postmenopausal defined as 12 months of spontaneous amenorrhea
(in questionable cases a blood sample with simultaneous follicle stimulating hormone
[FSH] and estradiol levels consistent with menopause). Females on hormone replacement
therapy (HRT) and whose menopausal status is in doubt will be required to use one of
the highly effective contraception methods if they wish to continue their HRT during
the study. Otherwise, they must discontinue HRT to allow confirmation of
post-menopausal status prior to study enrolment.

- Female of reproductive potential and agrees to follow one of the options listed in the
Modified List of Highly Effective Methods for Avoiding Pregnancy in Females of
Reproductive Potential (FRP) from 30 days prior to the first dose of study medication
and until 2 weeks after dosing with study medication and completion of the follow-up
visit. The investigator is responsible for ensuring that subjects understand how to
properly use these methods of contraception.

- Capable of giving signed informed consent which includes compliance with the
requirements and restrictions listed in the consent form and in this protocol.

- Documentation that the subject is negative for the human leukocyte antigen
(HLA)-B*5701 allele.

Exclusion Criteria

- ALT and bilirubin >1.5xULN (isolated bilirubin >1.5xULN is acceptable if bilirubin is
fractionated and direct bilirubin <35%).

- Current or chronic history of liver disease, or known hepatic or biliary abnormalities
(with the exception of Gilbert's syndrome or asymptomatic gallstones).

- QT interval corrected for heart rate according to Fridericia's formula (QTcF) >450
milliseconds (msec). The specific formula that will be used to determine eligibility
and discontinuation for an individual subject should be determined prior to initiation
of the study. In other words, several different formulae cannot be used to calculate
the QTc for an individual subject and then the lowest QTc value used to include or
discontinue the subject from the trial.

- Unable to refrain from the use of prescription (i.e., dofetilide) or non-prescription
drugs, including vitamins, herbal and dietary supplements (including St John's Wort)
within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives
(whichever is longer) prior to the first dose of study medication, unless in the
opinion of the Investigator and GSK Medical Monitor the medication will not interfere
with the study procedures or compromise subject safety.

- History of regular alcohol consumption within 6 months of the study defined as: An
average weekly intake of >14 drinks for males or >7 drinks for females. One drink is
equivalent to 12 gram of alcohol: 12 ounces (360 mL) of beer, 5 ounces (150 mL) of
wine or 1.5 ounces (45 mL) of 80 proof distilled spirits.

- Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or
nicotine-containing products within 1 month prior to screening.

- History of sensitivity to any of the study medications, or components thereof or a
history of drug or other allergy that, in the opinion of the investigator or Medical
Monitor, contraindicates their participation.

- Creatinine clearance (CrCL) <60 mL/min

- Presence of HBsAg, positive hepatitis C antibody test result at screening or within 3
months prior to first dose of study treatment.

- A positive pre-study drug/alcohol screen.

- A positive test for HIV antibody.

- Where participation in the study would result in donation of blood or blood product in
excess of 500 mL within 56 days.

- The subject has participated in a clinical trial and has received an investigational
product within the following time period prior to the first dosing day in the current
study: 30 days, 5 half-lives or twice the duration of the biological effect of the
investigational product (whichever is longer).

- Exposure to more than four new chemical entities within 12 months prior to the first
dosing day.